119783-91-4

Usage

InChI:InChI=1/C22H43FN6O9/c23-14-18(37-21-9(26)2-1-8(6-25)35-21)10(27)5-11(29-20(34)12(31)3-4-24)19(14)38-22-17(33)15(28)16(32)13(7-30)36-22/h8-19,21-22,30-33H,1-7,24-28H2,(H,29,34)/t8-,9+,10-,11+,12-,13+,14-,15-,16+,17+,18+,19-,21+,22+/m0/s1

Upstream product

• 173009-70-6 5,3',4'-trideoxy-5-epifluorokanamycin B 
• 78740-48-4 3',4'-dideoxy-1,3,2',6',3''-pentakis(N-tert-butoxycarbonyl)kanamycin B 
• 118811-73-7 C₄₄H₅₃F₄N₅O₁₄ 

Relevant academic research and scientific papers

Effect of varying the 4″-position of arbekacin derivatives on antibacterial activity against MRSA and Pseudomonas aeruginosa

4″-Deoxy-4″-episubstituted arbekacin derivatives and 4″-epi-5-deoxy-5-episubstituted arbekacin derivatives were designed and synthesized. Arbekacin and 4″-epiarbekacin both displayed the same antibacterial activity against Staphylococcus aureus (including

NOVEL AMINOGLYCOSIDE ANTIBIOTIC EFFECTIVE AGAINST METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)

Disclosed are compounds represented by general formula (I) or pharmacologically acceptable salts or solvates thereof having excellent antimicrobial activity against bacteria causative of severe infections such as pneumonia and septicemia, particularly against MRSA, and also antimicrobial agents comprising these compounds, and pharmaceutical compositions comprising these compounds as an active component.

Synthesis of 5-deoxy-5-epifluoro derivatives of arbekacin, amikacin and 1-N-tobramycin (study on structure - toxicity relationships)

As part of a study on fluorination-toxicity relationships for aminoglycoside antibiotics, 5,3'-dideoxy-5-epifluorokanamycin B (10), 5,3',4'-trideoxy-5-epifluorokanamycin B (11), 1-N--5-deoxy-5-epifluorotobramycin (19), 5-deoxy-5-epifluoroarbekacin (20), and 5-deoxy-5-epifluoroamikacin (21) have been prepared.The acute toxicities of these three 5-deoxy-5-epifluoro compounds showed values almost identical or similar to those for arbekacin (ABK) and amikacin (15), making a sharp contrast with the toxicities of the corresponding 5-deoxy-5-fluoro derivatives.This fact is explained on the basis of basicity changes (retention for the 5-epifluoro derivatives and reduction for the 5-fluoro derivatives) at the H2N-3 groups of the fluorinated compounds compared to the parent compounds; this hypothesis was substantiated by the pKa values at the H3N1+-1,3-groups (determined by the shift changes depending on pD values at C-2 and C-4, 6 in their 13C NMR spectra) of 2,5-dideoxy-5-epifluorostreptamine (23) and 2,5-dideoxy-5-fluorostreptamine (24), chosen as model compounds, and 2-deoxystreptamine (DST). Keywords: Arbekacin; Amikacin; 1-N-(S)-4-Amino-2-hydroxybutanoyl)tobramycin